United States Daily Briefing

With fresh CPI data driving rate-hike repricing, Amgen's continued outperformance reflects investor rotation into large-cap pharma with non-cyclical revenue streams. SeekingAlpha analysis confirms the fundamental thesis remains intact: pricing power plus pipeline depth makes AMGN a credible safe harbor when growth names compress. The read for tomorrow is whether AbbVie's +4.2% and Amgen's resilience extend into a broader healthcare/defensive momentum trade, or whether the Nasdaq's single-day decline prompts a buy-the-dip rotation back into growth.

SeekingAlpha downgraded Primoris (PRIM) to Hold after a June reset that the analyst characterized as worrisome, flagging margin compression in infrastructure services. This is a canary-in-the-coal-mine for US industrials: infrastructure names have been insulated from the tech rotation narrative, but when EPC contractors start showing earnings pressure, the broader capex cycle read weakens. Watch Primoris Q2 print for confirmation — if the June reset translates into a miss, it validates cautious positioning in cyclical infrastructure names.

Canada's TSX gained on gold-sector strength while US markets slid — a divergence that signals gold's safe-haven bid is strengthening relative to US equity risk premia. Advisor.ca reported basic materials lifting the TSX even as US markets sold off on inflation data, which is a cross-asset read that validates rotating into commodity-linked Canadian equities as a dollar hedge when US rate-hike risk spikes. The CAD basis divergence from the Fed-BoC spread watch is tightening — worth monitoring if gold continues outperforming Thursday's close.